Strategic asset sale TC BioPharm recently sold assets to CytoMed Therapeutics, signaling a potential openness to partnerships or asset acquisition discussions that could be explored for portfolio alignment or licensing opportunities.

Public investor visibility Active participation in investor events and a NASDAQ ticker indicate heightened visibility with investors and potential buyers; leverage these channels for outreach, joint ventures, or strategic collaborations.

Financing momentum Recent non-dilutive and equity injections show ongoing fundraising activity while aiming to reduce cash burn; opportunities may exist to offer CRO, manufacturing, or analytical services to support cost-efficient development.

AI enabled screening Collaboration with a major university to develop AI for donor screening and matching opens doors for data analytics, workflow optimization, and software partnership opportunities around donor-recipient matching pipelines.

Portfolio expansion Interest in broadening the cell therapy portfolio, including infectious disease programs like Mpox, presents avenues for collaboration on GMP manufacturing, clinical trial support, and strategic co-development arrangements.